Immunoproteasome inhibitor formulations
US12357638B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 4, 2019 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Sep 12, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are pharmaceutical formulations comprising KZR-616 or a salt thereof, and a sugar, wherein the formulations are lyophilized, methods of preparing said formulations, methods of treating immune-related diseases, and methods of treating inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.